Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSF1A and P16 genes silenced in QBC cells

Chinese-German Journal of Clinical Oncology

Volumn 7, Issue 11, 2008, Pages 627-630

  Li, Hong ^a   Chen, Shaoqin ^a   Shu, Yi ^a   Chen, Yongjun ^a   Su, Ying ^a   Wang, Xin ^a   Zou, Shengquan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

DNA hypermethylation; DNA methyltransferase inhibitor; Genere expression; Histone deacetylase inhibitor

Indexed keywords

EID: 56449127265     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-008-0119-7     Document Type: Article

References (19)

1. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol, 2000, 249: 35-54.
2. Singh SM, Murphy B, O'Reilly RL. Involvement of gene-diet/drug interaction in DNA methylation and its contribution to complex diseases: from cancer to schizophrenia. Clin Genet, 2003, 64: 451-460.
3. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents, 2003, 3: 187-199.
4. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet, 2000, 25: 315-319.
5. Chen YJ, Tian QB, Zou SQ, et al. Express of different RASSF1 transcipts and its clinical significance in extrahepatic bile duct carcinoma. J Hepatobiliary Surg (Chinese), 2005, 11: 107-109.
6. Chen YJ, Tang QB, Zou SQ. Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma. World J Gastroenterol, 2005, 11: 1333-1338.
7. Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol, 2003, 18: 665-677.
8. Pfeifer GP, Yoon JH, Liu L, et al. Methylation of the RASSF1A gene in human cancers. Biol Chem, 2002, 383: 907-914.
9. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN 2/MTS1 in human cancers. Nat Med, 1995, 1: 686-692.
10. Yang B, House MG, Guo MZ, et al. Promoter methylation profiles of tumorsuppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Moden Pathol, 2005, 18: 412-420.
11. Zambrano P, Segura-Pacheco B, Perez-Cardenas E, et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer, 2005, 5: 44.
12. Chávez-Blanco A, Segura-Pacheco B, Pérez-Cárdenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer, 2005, 4: 22.
13. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 1996, 93: 9821-9826.
14. Rush LJ, Plass C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett, 2002,185: 1-12.
15. Chen WY, Zeng X, Carter MG, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet, 2003, 33: 197-202.
16. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res, 1995, 55: 4525-4530.
17. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001, 93: 691-699.
18. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta, 2002, 1602: 73-87.
19. Sharma D, Blum J, Yang X, et al. Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor alpha (ER) promoter upon reactivation in ER-Negative human breast cancer cells. Mol Endocrinol, 2005, 19: 1740-1751.